Loading...
XNASONCT
Market cap1mUSD
Dec 02, Last price  
0.53USD
Name

Oncternal Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:ONCT chart
P/E
—
P/S
1.99
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-2.49%
Rev. gr., 5y
-20.81%
Revenues
785k
-47.32%
1,867,0003,782,0007,505,0007,126,00013,528,00014,730,00060,613,00014,739,0000000-2,511,0001,674,0002,521,0002,425,0003,375,0004,315,0001,490,000785,000
Net income
-39m
L-9.02%
-22,348,000-36,839,000-35,510,000-40,359,000-51,780,000-46,256,00015,294,000-33,294,000-27,075,000-42,111,000-39,411,000-18,703,000-17,724,000-30,439,000-38,418,000-15,912,000-17,209,000-31,300,000-43,393,000-39,479,000
CFO
-32m
L-12.37%
-15,671,000-34,819,000-11,460,000-37,634,000-2,925,000-45,997,000-30,527,000-33,089,000-37,109,000-43,971,000-28,759,000-20,035,000-20,778,000-23,460,000-39,346,000-16,746,000-17,495,000-26,589,000-36,704,000-32,164,000
Earnings
Mar 05, 2025

Profile

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
URL
https://www.oncternal.com/
IPO date
Feb 03, 2004
Employees
30
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
785
-47.32%
1,490
-65.47%
4,315
27.85%
Cost of revenue
72,252
46,616
35,850
Unusual Expense (Income)
NOPBT
(71,467)
(45,126)
(31,535)
NOPBT Margin
Operating Taxes
(777)
(33)
Tax Rate
NOPAT
(71,467)
(44,349)
(31,502)
Net income
(39,479)
-9.02%
(43,393)
38.64%
(31,300)
81.88%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,068
9,579
617
BB yield
-3.39%
-18.21%
-0.55%
Debt
Debt current
173
87
75
Long-term debt
463
87
75
Deferred revenue
Other long-term liabilities
1,334
3,004
Net debt
(33,619)
(63,550)
(90,615)
Cash flow
Cash from operating activities
(32,164)
(36,704)
(26,589)
CAPEX
Cash from investing activities
651
(26,498)
Cash from financing activities
1,068
9,579
617
FCF
(71,638)
(44,361)
(31,537)
Balance
Cash
34,255
63,724
90,765
Long term investments
Excess cash
34,216
63,650
90,549
Stockholders' equity
(197,773)
(158,234)
(114,081)
Invested Capital
229,477
219,290
26
ROIC
ROCE
EV
Common stock shares outstanding
2,940
2,630
2,466
Price
10.72
-46.38%
20.00
-55.95%
45.40
-53.67%
Market cap
31,529
-40.05%
52,594
-53.02%
111,959
12.53%
EV
(2,090)
(10,956)
21,344
EBITDA
(71,467)
(45,201)
(31,366)
EV/EBITDA
0.03
0.24
Interest
702
Interest/NOPBT